Netflix, Inc. (NFLX) saw its value increase by 0.47% as the stock gained $0.61 to finish the day at a closing price of $130.5. The stock was lighter in trading and has fluctuated between $79.95-$133.88 per share for the past year. The shares are up by 29.73% in the past three months and up by 35.33% over the past six months. It is currently trading 3.1% above its 20 day moving average and 6.58% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $124.35 a share over the next twelve months. The current relative strength index (RSI) reading is 64.43.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic streaming, International streaming and Domestic DVD. It offer members with the ability to receive TV shows and movies streaming content, including original series, documentaries, and feature films through a host of Internet-connected screens, such as TVs, digital video players, TV set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. As of October 17, 2016, it served approximately 86 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California.
CenturyLink, Inc. (CTL) shares were up in last trading by 0.16% to $25.24. It experienced lighter than average volume on day. The stock decreased in value by almost -0.94% over the past week and grew 4.64% in the past month. It is currently trading 3.98% above its 50 day moving average and -6.42% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -22.89% decrease in value from its one year high of $33.45. The RSI indicator value of 63.24, lead us to believe that it is a hold for now.
CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.
Sarepta Therapeutics, Inc. (SRPT) opening the day at $38.24. The company has seen its stock increase in value by 29.6% so far this year. The stock was down close to -6.18% on active volume in last trading session and closed at $35.55 per share. After the recent fall, the stock is currently holding -44.22% below its 52 week high of $63.73 and 344.37% above its 12-month low of $8. The shares are down by over -33.95% in the last three months, and the RSI indicator value of 59.51 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. The companys lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development for the treatment of individuals with Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease caused by the absence of dystrophin. It is also developing exon-skipping drugs for the treatment of DMD; and therapeutic candidates for the treatment of infectious diseases, such as influenza, Marburg, and Ebola. The company has a strategic alliance with Charleys Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies; a license agreement with the University of Western Australia for the use of antisense sequences in the treatment of DMD; and a research collaboration agreement with Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.